Role of mutagenicity in asbestos fiberinduced carcinogenicity and other diseases, J Toxicol Environ Health B Crit Rev, vol.14, issue.1-4, pp.179-245, 2011. ,
,
State of the Art: Concise Review Scientific Advances and New Frontiers in Mesothelioma Therapeutics, J Thorac Oncol, 2018. ,
, Biomolecular Pathways and Malignant Pleural Mesothelioma
URL : https://hal.archives-ouvertes.fr/inserm-02479956
, Malignant Pleural Mesothelioma: Present Status and Future Directions, pp.169-192, 2016.
,
,
Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations, Nature genetics, vol.48, issue.4, pp.407-423, 2016. ,
,
,
Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition, Clin Cancer Res, vol.20, issue.5, pp.1323-1357, 2014. ,
URL : https://hal.archives-ouvertes.fr/inserm-02478599
,
Co-occurring mutations of tumor suppressor genes, LATS2 and NF2, in malignant pleural mesothelioma, Clin Cancer Res, vol.23, issue.12, pp.3191-3202, 2017. ,
URL : https://hal.archives-ouvertes.fr/inserm-02478604
,
French Cooperative Thoracic Intergroup, Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, Lancet, vol.387, pp.1405-1419, 2016. ,
Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma, Expert Opin Investig Drugs, vol.26, issue.8, pp.933-944, 2017. ,
The importance of molecular markers for diagnosis and selection of targeted treatments in patients with cancer, Journal of Internal Medicine, vol.278, issue.6, pp.545-570, 2015. ,
Novel biomarkers in cancer: The whole is greater than the sum of its parts, Seminars in Cancer Biology, vol.45, pp.50-57, 2017. ,
,
,
Differential mutation profiles and similar intronic TP53 polymorphisms in asbestos-related lung cancer and pleural mesothelioma, Mutagenesis, vol.28, issue.3, pp.323-354, 2013. ,
URL : https://hal.archives-ouvertes.fr/inserm-02478590
,
Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma, Oncogene, vol.33, issue.28, pp.3748-52, 2014. ,
URL : https://hal.archives-ouvertes.fr/inserm-02478602
,
Syntenic Relationships between Genomic Profiles of Fiber-Induced Murine and Human Malignant Mesothelioma, Am J Pathol, vol.178, issue.2, pp.881-94, 2011. ,
URL : https://hal.archives-ouvertes.fr/inserm-00531343
,
In vitro effects of recombinant human interferon gamma on human mesothelioma cell lines, Int J Cancer, vol.55, issue.3, pp.515-535, 1993. ,
ATM has a major role in the double-strand break repair pathway dysregulation in sporadic breast carcinomas and is an independent prognostic marker at both mRNA and protein levels, British Journal of Cancer, vol.112, issue.6, pp.1059-1066, 2015. ,
,
Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship, Science translational medicine, vol.6, issue.237, pp.237-68, 2014. ,
Novel therapies for malignant pleural mesothelioma, Lancet Oncol, vol.19, issue.3, pp.161-172, 2018. ,
,
Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells, Nucleic Acids Res, vol.41, pp.955-61, 2013. ,
,
A Novel Small-Molecule Inhibitor of Transforming Growth Factor ? Type I Receptor Kinase (SM16) Inhibits Murine Mesothelioma Tumor Growth In vivo and Prevents Tumor Recurrence after Surgical Resection, Cancer Research, vol.67, issue.5, pp.2351-2359, 2007. ,
Molecular changes in mesothelioma with an impact on prognosis and treatment, Archives of pathology & laboratory medicine, vol.136, issue.3, pp.277-93, 2012. ,
URL : https://hal.archives-ouvertes.fr/inserm-02478588
, Trametinib plus 4-Methylumbelliferone Exhibits Antitumor Effects by ERK Blockade and CD44 Downregulation and Affects PD-1 and PD-L1 in
, Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer, vol.12, issue.3, pp.477-490, 2017.
A Phosphotyrosine Proteomic Screen Identifies Multiple Tyrosine Kinase Signaling Pathways Aberrantly Activated in Malignant Mesothelioma, Genes Cancer, vol.1, issue.5, pp.493-505, 2010. ,
Dasatinib modulates sensitivity to pemetrexed in malignant pleural mesothelioma cell lines, Oncotarget, vol.7, issue.47, pp.76577-76589, 2016. ,
,
Nonamplified FGFR1 is a growth driver in malignant pleural mesothelioma, Molecular cancer research: MCR, vol.12, issue.10, pp.1460-1469, 2014. ,
,
,
Fibroblast growth factor receptor inhibition is active against mesothelioma and synergizes with radio-and chemotherapy, American journal of respiratory and critical care medicine, vol.190, issue.7, pp.763-772, 2014. ,
A link between the fibroblast growth factor axis and the miR-16 family reveals potential new treatment combinations in mesothelioma, Molecular Oncology, vol.12, issue.1, pp.58-73, 2018. ,
,
Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin, British Journal of Cancer, vol.105, issue.10, pp.1542-1553, 2011. ,
Extracellular signal-regulated kinase 5 and cyclic AMP response element binding protein are novel pathways inhibited by vandetanib (ZD6474) and doxorubicin in mesotheliomas, American journal of respiratory cell and molecular biology, vol.51, issue.5, pp.595-603, 2014. ,
,
Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models and Inhibits Angiogenesis and Tumor Growth In Vivo, Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 2018. ,
Role of the PDZ-scaffold protein NHERF1/EBP50 in cancer biology: from signaling regulation to clinical relevance, Oncogene, vol.36, issue.22, pp.3067-3079, 2017. ,
,
Small molecule inhibitors of ezrin inhibit the invasive phenotype of osteosarcoma cells, Oncogene, vol.31, issue.3, pp.269-281, 2012. ,
E-cadherin expression is correlated with focal adhesion kinase inhibitor resistance in Merlin-negative malignant mesothelioma cells, Oncogene, vol.36, issue.39, pp.5522-5531, 2017. ,
Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP, Genes Dev, vol.26, issue.12, pp.1300-1305, 2012. ,
,
YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cycle-promoting genes, Oncogene, vol.31, issue.49, pp.5117-5139, 2012. ,
,
,
Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study, Arch Ophthalmol, vol.117, issue.9, pp.1161-73, 1999. ,
Targeting YAP in malignant pleural mesothelioma, J Cell Mol Med, vol.21, issue.11, pp.2663-2676, 2017. ,
Methylation profile landscape in mesothelioma: possible implications in early detection, disease progression, and therapeutic options, Methods Mol Biol, vol.1238, pp.235-282, 2015. ,
Verteporfin exhibits YAPindependent anti-proliferative and cytotoxic effects in endometrial cancer cells, Oncotarget, vol.8, issue.17, pp.28628-28640, 2017. ,
Lumican inhibits cell migration through ?2?1 integrin, Experimental Cell Research, vol.316, issue.17, pp.2922-2931, 2010. ,
Cancer-associated fibroblast-derived Lumican promotes gastric cancer progression via the integrin ?1-FAK signaling pathway, International Journal of Cancer, vol.141, issue.5, pp.998-1010, 2017. ,
Molecular cloning and characterization of a novel member of the MAP kinase superfamily, Genes to Cells: Devoted to Molecular & Cellular Mechanisms, vol.4, issue.5, pp.299-309, 1999. ,